A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Trial Profile

A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Avelumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Ovarian cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms JAVELIN Ovarian 100
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 Apr 2017 Planned End Date changed from 6 Sep 2019 to 1 Dec 2021.
    • 06 Jul 2016 According to Merck media release, Merck and Pfizer announced the initiation of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top